Vanda Pharmaceuticals (VNDA) Net Income towards Common Stockholders (2010 - 2026)

Vanda Pharmaceuticals has reported Net Income towards Common Stockholders for 17 years, with the latest figure at -$48.5 million in Q1 2026.

• Quarterly Net Income towards Common Stockholders fell 64.52% year-over-year to -$48.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$239.5 million (down 441.44% YoY) and the FY2025 annual result came in at -$220.5 million, down 1066.53% from the prior year.
• Net Income towards Common Stockholders climbed to -$48.5 million in Q1 2026 per VNDA's latest filing, from -$141.2 million in the prior quarter.
• Over five years, Net Income towards Common Stockholders peaked at $6.9 million in Q4 2022 and troughed at -$141.2 million in Q4 2025.
• A 5-year average of -$16.4 million and a median of -$4.5 million in 2024 frame the typical range for Net Income towards Common Stockholders.
• The sharpest annual moves came in 2023 and 2024: Net Income towards Common Stockholders soared 149.94% in 2023, then plunged 4000.73% in 2024.
• Over 5 years, Net Income towards Common Stockholders stood at $6.9 million in 2022, then plunged by 134.85% to -$2.4 million in 2023, then sank by 103.93% to -$4.9 million in 2024, then tumbled by 2795.55% to -$141.2 million in 2025, then jumped by 65.63% to -$48.5 million in 2026.
• According to Business Quant data, Net Income towards Common Stockholders over the past three periods registered -$48.5 million, -$141.2 million, and -$22.6 million for Q1 2026, Q4 2025, and Q3 2025 respectively.